Kidney Cancer

This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.

Cabozantinib plus nivolumab and ipilimumab conferred a significant PFS benefit vs. nivolumab and ipilimumab alone among patients with advanced renal cell carcinoma, according to results of the COSMIC-313 trial presented at ESMO Congress.

Targeted cancer therapy had a higher association with risk for major adverse cardiovascular events than cytokine therapy among patients with advanced renal cell carcinoma, according to study results.

Although the number of Americans insured through Medicaid has increased during the past decade, barriers to cancer care access exist among Medicaid beneficiaries across high-quality centers, according to study results in JAMA Network Open.

Part A of a phase 3 trial assessing adjuvant nivolumab and ipilimumab for certain patients with renal cell carcinoma failed to meet the primary endpoint of DFS, according to topline data released by the agents’ manufacturer.

Donna Hansel, MD, PhD, has been named division head of pathology and laboratory medicine at The University of Texas MD Anderson Cancer Center.

CHICAGO — Better health-related quality of life was linked to longer survival in patients with intermediate- or poor-risk renal cell carcinoma, according to an analysis of the CheckMate 214 trial.

In this video, Nancy Moldawer, RN, MSN, discussed new treatments in kidney cancer and how to apply nursing strategies to best meet the needs of patients with renal cell carcinoma.

Sumanta K. Pal, MD, co-director of Kidney Cancer Program at City of Hope, and a HemOnc Today Editorial Board Member, spoke with Healio about studies on renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.

In this video, Mark W. Ball, MD, discusses the ongoing SWOG S1931 study assessing the use of immune checkpoint inhibitors with or without cytoreductive nephrectomy in patients with renal cell carcinoma.